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Summary
 
The mechanisms that govern leukocyte transmigration through the endothelium are not yet
fully defined. Junctional adhesion molecule (JAM) is a newly cloned member of the immuno-
globulin superfamily which is selectively concentrated at tight junctions of endothelial and epi-
thelial cells. A blocking monoclonal antibody (BV11 mAb) directed to JAM was able to inhibit
monocyte transmigration through endothelial cells in in vitro and
 
 
 
in vivo chemotaxis assays. In
this study, we report that BV11 administration was able to attenuate cytokine-induced menin-
gitis in mice. The intravenous injection of BV11 mAb significantly inhibited leukocyte accumu-
lation in the cerebrospinal fluid and infiltration in the brain parenchyma. Blood–brain barrier
permeability was also reduced by the mAb. We conclude that JAM may be a new target in lim-
iting the inflammatory response that accompanies meningitis.
Key words: endothelium • tight junction • meningitis • vascular permeability •
blood–brain barrier
 
M
 
aintenance of cerebral homeostasis requires a strict
control of the extravascular traffic of cells and macro-
molecules from blood to the cerebrospinal fluid (CSF) and
brain parenchyma. In physiological conditions, this task is
well accomplished by both the epithelial lining that covers
choroid plexus vessels, and the highly impermeable endo-
thelium of cerebral capillaries which penetrates the brain pa-
renchyma and constitutes the blood–brain barrier (1, 2).
However, in acute inflammatory states such as bacterial
meningitis, the processes that regulate blood–brain barrier
functions are severely modified, thus bringing about diffused
leukocyte invasion in CSF and brain parenchyma, which con-
tributes to a severe pathological alteration of cerebral function
(3–6). Inhibition of leukocyte recruitment (7, 8) has been
shown to reduce protein accumulation in the CSF and im-
prove the survival rate in experimental models of meningitis.
The mechanisms that regulate leukocyte passage through
endothelial cells and infiltration at inflammatory sites are
still largely obscure. It is currently believed that leukocytes
leave the circulation by first adhering to endothelial cells
and then migrating through the interendothelial junctions
(9, 10). However, a few morphological studies reported
that leukocytes may traverse endothelial cells through trans-
cellular pathways (11).
Endothelial cell–cell junctions are complex structures
formed by different adhesive molecules. At least two types
of junctional adhesive structures have been described in the
endothelium (12, 13): the adherens junctions (AJs) formed
by clusters of transmembrane proteins belonging to the cad-
herin family and the tight junctions (TJs). The transmem-
brane proteins at TJs are occludin (14) and a recently iden-
tified tetraspan protein family called claudins (15). These
proteins codistribute with a complex network of cytoskele-
tal and signaling proteins inside the cells (16). These struc-
tures present common features between endothelial and
epithelial cells.
Endothelial cells express several other adhesive proteins
at intercellular contacts located outside AJs and TJs (5, 13).
Platelet endothelial cell adhesion molecule (PECAM) is one
of the most relevant. It is a member of the immunoglobulin
superfamily, promotes endothelial homotypic adhesion, and
is clustered at intercellular contacts. Antibodies directed to
PECAM are able to inhibit leukocyte transmigration in
 
 
 
in
vitro and in vivo systems (17–19). 
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We have recently identified and cloned a new junctional
molecule in endothelial and epithelial cells called JAM (for
junctional adhesion molecule [20]). JAM is a small trans-
membrane immunoglobulin-like molecule that codistrib-
utes with TJ components and promotes homotypic cell–cell
adhesion (20). An mAb directed to JAM (BV11) was found
to inhibit spontaneous and chemokine-induced chemotaxis
of monocytes (20). JAM is highly expressed in cells that
present well-organized TJs, such as the ependymal cells and
the endothelium of the blood–brain barrier (20).
In this paper, we studied the effect of BV11 on experi-
mental meningitis induced by intracerebroventricular (ICV)
injection of inflammatory cytokines in mice (21). This model
is characterized by a significant inflammatory cell influx and
increase in blood–brain barrier permeability. The data re-
ported show that JAM inhibition blocked monocyte and
neutrophil infiltration into the CSF and brain parenchyma.
In addition, albumin influx in CSF was strongly reduced by
the JAM mAb. These data strongly suggest that functional
blocking of JAM may provide a novel approach in limiting
acute inflammatory reactions.
 
Materials and Methods
 
Reagents.
 
Reagents were purchased from the following sources:
RPMI 1640, PBS, and FCS from GIBCO BRL; Immu-Mount
from Shandon; OCT compound from Miles Labs; 
 
N
 
-cetyl-
 
N
 
,
 
N
 
,
 
N
 
-
trimethyl-ammonium bromide (TAB), Genziana violet, BSA,
chloral hydrate, dianisidine dihydrochloride, erythrosine, FITC-
conjugated bovine albumin (FITC-albumin), and heparin from
Sigma Chemical Co.; human TNF-
 
a
 
 from Genzyme Corp.; hu-
man IL-1
 
b
 
 from Dompè; human monocyte chemotactic protein 3
(MCP-3) from Peprotech; Diff-Quik from Baxter Dade AG.
 
Animals.
 
CD1 male mice (25–30 g; Charles River) were housed
with free access to food and water, under a 12-h light–dark cycle
with constant temperature (21–23
 
8
 
C) and humidity (60
 
 6 
 
5%).
Procedures involving animals and their care were conducted in
conformity with institutional guidelines that are in compliance
with international laws and policies (European Economic Com-
munity Council Directive 86/609, OJ L 358,1; Dec. 12, 1987;
National Institutes of Health Guide for the Care and Use of Lab-
oratory Animals, NIH Publication No. 85-23, 1985).
 
Antibodies.
 
All the antibodies, unless otherwise specified, were
rat anti–mouse mAbs and were used as sterile purified immuno-
globulins. BV11 and BV12 mAbs were generated in our labora-
tory following a previously described procedure and characterized
as described (20, 22). BV12 recognizes a different JAM epitope
than BV11 and is devoid of biological activity (20). Fab fragments
of BV11 were prepared by standard procedures (23). Other anti-
bodies used in this study were as follows: (a) HB-151, anti–HLA-
DR5, used as isotype-matched control of BV11 (American Type
Culture Collection); (b) MEC 7.46 to PECAM (22); (c) RB6-8C5
to granulocyte-differentiation antigen (CD15) was obtained from
Dr. R.L. Coffman (DNAX, Palo Alto, CA). Endotoxin content
of all the mAbs was tested by the Limulus assay with chromoge-
nic detection (BioWhittaker). Tetramethyl rhodamine isothiocy-
anate (TRITC)-conjugated rabbit anti–rat IgG from Sigma Chem-
ical Co. was used as secondary antibody in immunofluorescence
microscopy.
 
Experimental Model of Meningitis.
 
A polyethylene cannula was
permanently implanted in the right lateral ventricle (0.5 mm lat-
 
eral and 1.0 mm posterior to bregma) 4 d before the onset of the
experiment, as described elsewhere (24). At time 0, the animals
were treated intravenously with mAbs at a standard dose of 100
 
m
 
g/mouse in a final volume of 100 
 
m
 
l or with 100 
 
m
 
l of sterile,
pyrogen-free saline. The dose of 100 
 
m
 
g/mouse for the mAbs
was selected as the optimal dose to inhibit monocyte chemotaxis
in vivo (20). After 10 min, mice were subjected to ICV treatment
with a mixture of TNF-
 
a
 
 (3 U/g) and IL-1
 
b
 
 (1.25 U/g) dissolved
in saline in a final volume of 2.5 
 
m
 
l (sham-injected animals received
the same volume of saline). In a different set of experiments, ani-
mals were ICV-treated with 1 
 
m
 
g/mouse of MCP-3. After 6 h of
treatment (except where otherwise specified), mice were anes-
thetized intraperitoneally with chloral hydrate (350 mg/kg), and
5–10 
 
m
 
l of CSF was drawn from the cisterna magna using a glass
capillary with a tip of 
 
z
 
300 
 
m
 
m (24). Careful surgery was con-
ducted in order to avoid blood contamination of CSF. Mice were
then decapitated, and brains were immediately cooled by liquid ni-
trogen and stored at 
 
2
 
80
 
8
 
C until measurement of myeloperoxidase
(MPO) activity or included in OCT compound, frozen in isopen-
tane cooled by liquid nitrogen, and stored to 
 
2
 
80
 
8
 
C, until prepa-
ration of brain tissue sections for immunofluorescence microscopy.
 
Quantitation of CSF and Total Blood Leukocytes.
 
CSF aliquots
(2 
 
m
 
l) were immediately diluted in cool RPMI (containing 10%
FCS) and kept in ice until cytospin centrifugation. Differential
leukocyte counts of CSF samples were determined on Diff-Quik–
fixed and erythrosine-stained cytospun slides by phase–contrast
microscopy. Total blood leukocyte counts were determined by
phase–contrast microscopy in heparin-anticoagulated blood diluted
with Turk solution (1:20 [20]).
 
Immunofluorescence Microscopy.
 
Infiltrated leukocytes and vas-
cular antigens were localized in brain tissue sections by immuno-
fluorescence microscopy (20, 24). Serial cryostat sections (20 
 
m
 
m)
were cut horizontally from the brain, placed on glass coverslips,
and dried overnight at room temperature (24). Tissue sections
were fixed in cool methanol (5 min at 
 
2
 
20
 
8
 
C), rinsed two times
with PBS, incubated in PBS containing 2% of BSA (30 min at
room temperature), and subsequently incubated for 1 h at room
temperature with TRITC-conjugated anti–rat IgG and rinsed
(three times, 5 min each) in PBS. Dried coverslips were then
mounted in Immu-Mount, observed in a Zeiss Axiophot micro-
scope, and images were recorded on Kodak TMax P3200 films.
 
Measurement of MPO Activity.
 
MPO activity was measured as
described previously (25, 26). In brief, the frozen tissues were
weighed and homogenized in 20 volumes of 5 mM PBS, pH 6.0,
at 4
 
8
 
C and then centrifuged at 30,000 
 
g
 
 (30 min at 4
 
8
 
C). Super-
natants were discarded, and pellets were extracted in 10 volumes
of 0.5% TAB in 50 mM PBS, pH 6.0, at 25
 
8
 
C. Samples were fro-
zen on dry ice (three freeze–thaw cycles) and then sonicated for
10 s at 25
 
8
 
C. Samples were subsequently incubated for 20 min at
4
 
8
 
C, centrifuged at 12,500 
 
g
 
 for 15 min at 4
 
8
 
C, and MPO assay
was performed as described (26, 27). The absorbance change (
 
D
 
A)
at 460 nm was measured over 2 min in the thermoregulated flow cell
(25
 
8
 
C) of a Uvikon 860 spectrophotometer (Kontron Instruments).
The data were derived using a kinetic computer program (26).
 
In Vivo Permeability Assay.
 
Sham- or cytokine-treated mice (with
or without mAb pretreatment) were injected intravenously with
FITC-albumin (1.5 mg/mouse) 1 h before time of killing. CSF
was collected as usual, and 4 
 
m
 
l was immediately diluted in 100 
 
m
 
l
of ice-cold phosphate buffer and kept at 4
 
8
 
C. Samples were then
placed in a 96-well microtiter plate, and fluorescence content was
measured in a fluorimeter (Cytofluor 2300 Fluorescence Measure-
ment System; Millipore Co.) at 492-nm absorbance and 520-nm
emission wavelengths, respectively. 
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Figure 2. (A) Time course of leukocyte accumulation in the CSF (a) or
brain parenchyma (b) after ICV injection of IL-1b and TNF-a. (a) The
inflammatory cytokines caused a marked increase of CSF neutrophils (d)
and monocytes (s). Data are expressed as percentage of total cell number
in CSF counted after cytokine administration. The number of cells in
sham-treated animals was essentially undetectable (see also B, panel a).
Data are means 6 SD of not less than five animals for each point from a
typical experiment out of six performed. (b) MPO accumulation in the
brain, as a parameter of leukocyte infiltration, was enhanced in a time-
dependent manner. Data are means 6 SD of at least five animals for each
point from a typical experiment out of five performed. (B) Representative
CSF samples collected at time 0 (a) and 6 h after ICV injection of cyto-
kines (b, c). BV11 administration (c) strongly reduced leukocyte accumu-
lation. (C) Administration of BV11 inhibited neutrophil and monocyte ac-
cumulation in the CSF after ICV cytokine injection. (a) BV11 and BV11
Fab significantly reduced neutrophil number in the CSF at 6 h after IL-1b
and TNF-a administration. mAbs BV12, directed to JAM, and HB-151, as
an isotype-matched control, were ineffective. (b) Monocyte accumulation
after IL-1b and TNF-a was significantly reduced by BV11 and BV11 Fab
but not by HB-151. Data are means 6 SD of at least five animals from a
typical experiment out of six performed. *P , 0.05; **P , 0.01 by analysis
of variance and Dunnet test compared with saline treatment.
 
Results
 
Vascular JAM staining was observed in brain tissue sec-
tions of sham- or cytokine-treated animals that had received
mAb BV11 in vivo. BV11 staining was evident in different
sized blood vessels that penetrate the brain parenchyma
(Fig. 1 a) and in those of choroid plexus (Fig. 1 b). No spe-
cific staining with the secondary antibody was observed
when the animals were treated with saline; when the mice
were treated with BV12 or when brain slices were treated
with BV11 in vitro,
 
 
 
we obtained a similar immunofluores-
cence pattern as that reported in Fig. 1 (not shown). No
major difference in JAM staining was observed in cytokine-
or sham-treated animals. These data confirm previous work
(20) showing that, despite the complex organization of the
TJs in the brain microvasculature, JAM is located more su-
perficially and can be available to mAb staining.
Mice ICV-treated with TNF-
 
a
 
 (3 U/g body wt) and IL-1
 
b
 
(1.25 U/g body wt) showed a time-dependent CSF recruit-
ment of both neutrophils and monocytes (Fig. 2 A, panel a).
Maximal neutrophil recruitment at 6 h was almost 90% of
the total leukocytes. Monocyte infiltration did not exceed
14% of the total recruited leukocytes. A comparable time
course of leukocyte recruitment, measured as MPO activity,
was observed in brain extracts of cytokine-treated mice (Fig.
2 A, panel b). After 6 h of treatment, cytokines induced a
3.7-fold increase of MPO activity compared with sham-
treated animals. As reported in Fig. 2 B, panel a, the CSF of
sham-treated animals was virtually devoid of circulating cells.
In contrast, CSF of cytokine-treated mice contained a large
number of recruited leukocytes (Fig. 2 B, panel b). This re-
sponse was markedly reduced by intravenous administration
of BV11 mAb (100 
 
m
 
g/mouse; Fig. 2 B, panel c).
mAb BV11 was able to reduce neutrophil accumulation
in the CSF by 
 
z
 
76%. This activity was retained by its Fab
fragment, whereas an isotype-matched control, mAb HB-
151, was ineffective (Fig. 2 C, panel a). mAb BV12, which
is able to bind JAM to a different epitope than BV11, did
not show a significant inhibitory activity (Fig. 2 C, panel a).
Monocyte recruitment was also reduced by 
 
z
 
50% by BV11
or its Fab fragments, whereas HB-151 was ineffective (Fig.
2 C, panel b). At a longer time, 9 h after treatment, inhibi-
Figure 1. Binding of anti-JAM
antibodies to brain vessels. Mice
were treated intravenously with
BV11 mAb. mAb binding was
evidenced by TRIC-conjugated
anti–rat IgG. BV11 was able to
bind vessels in the brain paren-
chyma (a) and in the choroid
plexus (b). 
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tion was still apparent, even if slightly lower, reaching 52% for
neutrophils (not shown). The inhibitory effect of BV11 was
observed also when mice were injected ICV with MCP-3
(1 
 
m
 
g/mouse [28]). Monocytes and neutrophils were effi-
ciently recruited by MCP-3 ICV, and their number was
significantly reduced in mice pretreated with BV11, but not
with HB-151 and BV12 (Fig. 3, a and b).
In all of the experiments reported above, the number of
circulating leukocytes was never substantially altered by in-
fusion of any type of mAb in cytokine- or sham-treated
mice. Blood samples were taken by puncture of the left
heart ventricle. In a typical experiment, in animals treated
ICV with IL-1
 
b
 
 and TNF-
 
a
 
 for 6 h, circulating leukocytes
were as follows: 9.1
 
 6 
 
2.2 
 
3 
 
10
 
6
 
/ml in saline; 8.3
 
 6 
 
1.3 
 
3
 
10
 
6 
 
in HB-151; 10.1
 
 6 
 
2 
 
3 
 
10
 
6
 
 in BV11; and 10.5
 
 6 
 
1.8 
 
3
 
10
 
6
 
 in BV12-treated animals. In comparison, in animals
treated ICV with saline for 6 h, circulating leukocytes were
as follows: 8.6
 
 6 
 
1.2 
 
3 
 
106/ml in saline; 8.8 6 1.1 3 106
in HB-151; 9.9 6 1.9 3 106 in BV11; and 9.5 6 1.2 3 106
in BV12-treated animals.
In addition, we were unable to detect increases in neutro-
phil trapping in lungs, spleen, liver, and kidneys by immu-
nofluorescence analysis of CD15-stained tissue sections in
animals treated with any of the mAbs used in this study.
As further control, we measured MPO activity (see be-
low) in lungs of mice treated for 6 h with saline, BV11, BV12,
HB-151 (100 mg/mouse), or BV11 Fab fragments (200 mg/
mouse). The values, expressed as DA/min/g, were not signif-
icantly different: 34.6 6 0.3 in saline; 27.6 6 0.2 in HB-151;
27.1 6 0.7 in BV12; 29.6 6 0.6 in BV11; and 26.8 6 0.7
in BV11 Fab–treated animals.
Neutrophil infiltration of the brain was also evaluated by
histological means. Brain tissue sections of sham-treated
mice showed essentially no staining of neutrophils with the
anti-CD15 mAb RB6-8C5 (Fig. 4 A, panels a and d). In
cytokine-treated mice, infiltrated neutrophils could be rec-
ognized in the surrounding areas of cerebral blood vessels
(Fig. 4 A, panel b) and in submeningeal spaces (Fig. 4 A,
panel e). Pretreatment of the mice with mAb BV11 (Fig.
4 A, panels c and f) but not with HB-151 (not shown) vis-
ibly reduced neutrophil extravasation.
To quantify leukocyte infiltration, we measured MPO
activity in brain extracts. The basal MPO activity was in-
creased by about three times in animals treated with TNF/
IL-1 and was reduced in mice pretreated with mAb BV11
but not with HB-151 (Fig. 4 B).
As another marker of acute inflammatory reaction in the
brain, we tested the effect of mAb BV11 on the extravasa-
tion of FITC-albumin. Cytokine treatment induced a 3.4-fold
increase of FITC-albumin extravasation in CSF (Fig. 5). This
enhancement of permeability was significantly reduced in
mice pretreated with mAb BV11 but not with the control
mAb, HB-151.
Discussion
As shown previously by others (29), the direct injection
of TNF-a and IL-1b ICV induces acute inflammatory re-
Figure 3. Administration of BV11 inhibited neutrophil and monocyte
accumulation in the CSF after ICV injection of MCP-3. BV11 signifi-
cantly reduced monocyte (a) and neutrophil (b) number in the CSF at 6 h
after MCP-3 administration, whereas mAbs HB-151 and BV12 were in-
effective. Data are means 6 SD of at least five animals from a typical ex-
periment out of three performed. *P , 0.01 by analysis of variance and
Dunnet test compared with saline treatment.
Figure 4. (A) Neutrophil infiltration in the brain detected by immu-
nofluorescence analysis of areas surrounding blood vessels (a–c) or sub-
meningeal space (d–f). Sham-treated animals showed essentially no stain-
ing with an anti-CD15 mAb (a and d). When mice were treated with IL-1b
and TNF-a for 6 h, a marked increase in neutrophil infiltration was ob-
served (b and e). This phenomenon was inhibited by BV11 administra-
tion (c and f). (B) MPO activity in brain extracts. ICV administration of
IL-1b and TNF-a increased MPO activity in the brain (compare sham
with saline). BV11 significantly reduced MPO accumulation, whereas
HB-151 and BV12 were ineffective. Data are means 6 SD of five animals
per group of a typical experiment out of four performed. *P , 0.01 ver-
sus saline treatment by analysis of variance and Dunnet test.1355 Del Maschio et al. Brief Definitive Report
actions in the brain parenchyma largely reminiscent of bac-
terial meningitis.
Reduction of inflammation in meningitis can decrease
mortality (3, 7, 30, 31). Inhibition of leukocyte adhesion to
endothelial cells by b2 integrin–blocking mAbs in bacterial
meningitis reduces CSF protein accumulation (7, 8) and
improves the survival rate. Furthermore, in mice deficient
in endothelial P- and E-selectins, leukocyte and protein in-
flux in the CSF upon inflammatory cytokine ICV injection
was virtually abolished (21).
In this paper, we extend these observations by showing
that inhibition of a novel leukocyte ligand, JAM, which
regulates leukocyte transmigration (20), is effective in reduc-
ing inflammatory reactions in experimental meningitis. In-
travenous pretreatment of mice with the anti-JAM mAb
BV11 strongly reduced leukocyte extravasation and albu-
min permeability in the CSF and brain parenchyma pro-
moted by ICV administration of cytokines.
The effect of BV11 was specific and not influenced by leu-
kocyte Fc receptor, since BV11 Fab fragments retained the
activity and an isotype-matched control mAb was ineffective.
In addition, BV12, an mAb directed to JAM but recognizing
a different epitope (20), was devoid of activity. Although in
previous work (20) we observed that JAM was important
in controlling monocyte extravasation, in the present model
we confirm and extend this observation to neutrophils, which
constitute the majority of the cellular exudate.
The effect of JAM appears to be specific for leukocyte
transmigration, since BV11 does not inhibit monocyte or
neutrophil adhesion to endothelial cells (20). In addition,
BV11 also reduced the effect of MCP-3 on CSF accumula-
tion of both cells types. MCP-3 does not induce endothe-
lial inflammatory reactions like IL-1b/TNF-a, and there-
fore these data are in favor of a specific effect of the mAb
on leukocyte recruitment.
Despite reduction in albumin influx in CSF, it is unlikely
that BV11 acts on endothelial permeability directly since it
did not modify basal or IL-1/TNF–increased endothelial
permeability in vitro in the absence of leukocytes (20; and
data not shown). A more likely hypothesis is that for its lo-
calization at intercellular junctions, JAM binds leukocytes
and directs their migration through the junctions. Since
leukocyte transmigration through cytokine-activated endo-
thelial cells may lead to an increase in permeability (32, 33),
JAM inhibition would cause an indirect protection of blood–
brain barrier breakdown.
A similar mechanism has been indicated for PECAM
(19), and it is possible that these two proteins constitute a
new class of agents which collaborate in promoting cell
movement through endothelial cell junctions. JAM is located
at TJs at the most apical domain of the intercellular cleft
(20), whereas PECAM is found at a more basal site of the
junctions (34). JAM may be necessary for the first interaction
of circulating cells, which would then move along the cleft.
An important issue is JAM counterreceptor in mono-
cytes and neutrophils. Monocytes and neutrophils obtained
from the peritoneal fluid of thioglycollate-injected mice (20)
or neutrophils from femoral bone marrow bind very poorly
mAbs BV11 and BV12. Therefore, it is conceivable that
these cells recognize JAM through a heterophilic receptor
and that this interaction is inhibited by BV11.
In conclusion, the data reported here support the concept
that JAM could constitute a novel target for modulating
leukocyte extravasation at sites of inflammation. Therefore,
manipulation of the molecular organization of endothelial
junctions may be an effective approach to control vascular
permeability and leukocyte traffic.
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